Kellner v. AIM Immunotech Inc.

CourtCourt of Chancery of Delaware
DecidedDecember 28, 2023
DocketC.A. No. 2023-0879-LWW
StatusPublished

This text of Kellner v. AIM Immunotech Inc. (Kellner v. AIM Immunotech Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kellner v. AIM Immunotech Inc., (Del. Ct. App. 2023).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

TED D. KELLNER, ) ) Plaintiff and ) Counterclaim-Defendant, ) ) v. ) C.A. No. 2023-0879-LWW ) AIM IMMUNOTECH INC., ) ) Defendant and ) Counterclaim-Plaintiff, ) ) and ) ) THOMAS EQUELS, WILLIAM ) MITCHELL, STEWART ) APPELROUTH, AND NANCY K. ) BRYAN, ) ) Defendants. )

OPINION

Date Submitted: December 5, 2023 Date Decided: December 28, 2023

John M. Seaman, Eric A. Veres & Eliezer Y. Feinstein, ABRAMS & BAYLISS LLP, Wilmington, Delaware; Jeffrey J. Lyons & Michael E. Neminski, BAKER & HOSTETLER LLP, Wilmington, Delaware; Teresa Goody Guillén, BAKER & HOSTETLER LLP, Washington, D.C.; Marco Molina, BAKER & HOSTETLER LLP, Costa Mesa, California; Ambika B. Singhal, BAKER & HOSTETLER LLP, Dallas, Texas; Alexandra L. Trujillo, BAKER & HOSTETLER LLP, Houston, Texas; Counsel for Ted D. Kellner William R. Denny, Matthew F. Davis, Nicholas D. Mozal & Caneel Radinson- Blasucci, POTTER ANDERSON & CORROON LLP, Wilmington, Delaware; Stefan Atkinson, Mary T. Reale & Mason E. Reynolds, KIRKLAND & ELLIS LLP, New York, New York; Michael F. Williams & Don Hong, KIRKLAND & ELLIS LLP, Washington, D.C.; Counsel for Thomas Equels, William Mitchell, Stewart Appelrouth, Nancy K. Bryan, and AIM ImmunoTech Inc.

WILL, Vice Chancellor This post-trial decision resolves an expedited action regarding the adoption

and enforcement of advance notice bylaws. It harkens back to a related case heard

last year and hints at what coming activism disputes may bring. One could say that

my holiday season was visited by litigation past, present, and future.

In 2022, a group schemed to run a proxy contest against AIM Immunotech

Inc. A dissident nomination was submitted after a potential director candidate asked

his friend to purchase AIM shares and front the attempt. The stockholder’s notice

raised the board’s suspicion that treachery was afoot since it appeared to be a

continuation of a prior failed nomination—one orchestrated by a felon who had

meddled with AIM’s business. Because the notice neglected to mention any

arrangement or understanding involving the broader group, as required by AIM’s

advance notice bylaws, it was rejected. The stockholder moved for a preliminary

injunction in this court, but the mandatory relief he sought was unprocurable on a

disputed factual record.

Now, a renewed nomination attempt is before me. It is, in many ways, smarter

than the preceding effort. The nomination is being pressed by a sophisticated

investor with a substantial number of AIM shares. Perhaps understanding the high

bar to obtaining a mandatory injunction on a preliminary record, he has taken his

claims through trial. Yet his notice suffers from the same primary defect as his

1 predecessor’s: it obscures obvious arrangements or understandings pertaining to the

nomination.

The plaintiff also lodged a facial challenge to a set of amended advance notice

bylaws recently adopted amid dark skies, arguing that they threaten stockholders’

ability to make future nominations. Several of the bylaws are so shrouded in layers

of murky text that their limits are a mystery. Reviewed through the lens of enhanced

scrutiny, they are disproportionate responses to any threatened corporate objectives.

Thus, the opinion that follows is a tale of wins and losses on both sides. As

with the past effort, the present nomination notice contravened valid bylaws. The

board’s rejection of the notice withstands inquiry. Certain bylaws, however, must

fall because they inequitably imperil the stockholder franchise to no legitimate end.

Perhaps these lessons will be heeded in matters still to come.

2 I. BACKGROUND

The following facts were stipulated to by the parties or proven by a

preponderance of the evidence at trial.1 The trial record includes the testimony of

10 fact and 2 expert witnesses, 22 deposition transcripts, and 1,241 joint exhibits.2

A. AIM ImmunoTech

AIM ImmunoTech Inc. (“AIM” or the “Company”) is an immuno-pharma

company incorporated in Delaware with its principal place of business in Ocala,

Florida.3 Its stock is traded on the NYSE American exchange.4 AIM’s stock price

has decreased by 99% since 2016 and it has a single drug with the requisite

regulatory approvals to be commercialized.5 The Company’s lead product is an

investigational drug called Ampligen, which is in clinical trials for immune system

disorders, viral diseases, and cancers.6

1 Joint Pre-trial Stipulation and Order (Dkt. 234) (“PTO”). 2 Facts drawn from exhibits jointly submitted by the parties are referred to by the numbers provided on the parties’ joint exhibit list and cited as “JX __” unless otherwise defined. Dkt. 253. Deposition transcripts are cited as “[Name] Dep.” See Dkts. 238-40, 252. Trial testimony is cited as “[Name] Tr.” See Dkts. 264-66. 3 PTO ¶ 10. 4 Id. 5 See JX 901 at 2; JX 701 at 8. 6 PTO ¶ 10. 3 AIM’s board of directors (the “Board”) has four members: Thomas Equels,

William Mitchell, Stewart Appelrouth, and Nancy K. Bryan.7 Equels, a lawyer by

training, is AIM’s Chief Executive Officer and has served on the Board since 2008.8

Mitchell, a physician, is a long-tenured Board member who serves as Chairman.9

He holds a Ph.D. in biochemistry and has studied Ampligen since its early

development in the mid-1980s.10 Appelrouth, an accountant, joined the Board in

2016.11 Bryan is the newest addition to the Board, having been appointed in March

2023.12 She is the President of BioFlorida, Inc., of which AIM is a member.13

B. Tudor’s Interest in AIM

AIM’s stockholder base is primarily composed of retail investors. One, Franz

Tudor, began to beset AIM management with frequent communications in the

summer of 2020. On July 30, 2020, Tudor sent a Twitter direct message to AIM’s

public relations manager advising on how to “be taken seriously.”14 Tudor stated: “I

7 Id. 8 Id. ¶ 11; Equels Tr. 494. Equels began his tenure at the Company while it was called Hemispherx. PTO ¶ 10. 9 PTO ¶ 12; Mitchell Tr. 630. 10 Mitchell Tr. 630-32. 11 PTO ¶ 13; Appelrouth Tr. 682. 12 PTO ¶ 14. 13 Id. 14 JX 45. 4 now represent over 1 mil[lion] shares b[etween] the various funds [I] consult and my

own ownership. Why do you think [the] stock didn’t break 2.65 today? That was

us buying every share sub 2.70.”15

Around the same time, Tudor contacted Equels and asked to obtain a position

as an international business development consultant for the Company.16 Equels

looked into Tudor’s background and learned that in 2009, Tudor pleaded guilty to

securities fraud and conspiracy to commit securities fraud as part of an insider

trading scheme at Galleon Group.17 Tudor is permanently enjoined from engaging

in certain activities related to penny stocks—a class of microcaps that includes

AIM.18

On August 4, Tudor emailed Equels to thank him for the “opportunity to assist

AIM in its business development initiatives.”19 AIM “pass[ed]” on Tudor’s

proposal.20 After losing touch with Equels, Tudor attempted to contact other Board

members and the Company’s investor relations representative.21 In a September 25

15 Id. at 2. 16 Tudor Dep. 55-56; see JX 362 (“Equels Aff.”) ¶ 6. 17 PTO ¶ 17. 18 Equels Aff. ¶ 5; see also id. Ex. A. 19 JX 47. Tudor also asked Equels if Ampligen could be shipped to his spouse’s family in Ecuador. JX 49 at 2. 20 JX 49 at 1. 21 JX 56; JX 79 at 161. 5 message to Appelrouth, Tudor said that he “represent[ed] some of AIM[’]s largest

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Mentor Graphics Corp. v. Quickturn Design Systems, Inc.
728 A.2d 25 (Court of Chancery of Delaware, 1998)
Lorillard Tobacco Co. v. American Legacy Foundation
903 A.2d 728 (Supreme Court of Delaware, 2006)
Blasius Industries, Inc. v. Atlas Corp.
564 A.2d 651 (Court of Chancery of Delaware, 1988)
Black v. Hollinger International Inc.
872 A.2d 559 (Supreme Court of Delaware, 2005)
In Re Osteopathic Hospital Association of Delaware
191 A.2d 333 (Court of Chancery of Delaware, 1963)
In Re Gaylord Container Corp. Shareholders Litigation
753 A.2d 462 (Court of Chancery of Delaware, 2000)
Openwave Systems Inc. v. Harbinger Capital Partners Master Fund I, Ltd.
924 A.2d 228 (Court of Chancery of Delaware, 2007)
Unitrin, Inc. v. American General Corp.
651 A.2d 1361 (Supreme Court of Delaware, 1995)
JANA Master Fund, Ltd. v. CNET Networks, Inc.
954 A.2d 335 (Court of Chancery of Delaware, 2008)
Portnoy v. Cryo-Cell International, Inc.
940 A.2d 43 (Court of Chancery of Delaware, 2008)
Hollinger International, Inc. v. Black
844 A.2d 1022 (Court of Chancery of Delaware, 2004)
Frantz Manufacturing Co. v. EAC Industries
501 A.2d 401 (Supreme Court of Delaware, 1985)
Carmody v. Toll Bros., Inc.
723 A.2d 1180 (Court of Chancery of Delaware, 1998)
Giuricich v. Emtrol Corp.
449 A.2d 232 (Supreme Court of Delaware, 1982)
In Re IBP, Inc., Shareholders Litigation
789 A.2d 14 (Court of Chancery of Delaware, 2001)
Fisher v. New Jersey State Parole Board
711 A.2d 293 (Supreme Court of New Jersey, 1998)
Chesapeake Corp. v. Shore
771 A.2d 293 (Court of Chancery of Delaware, 2000)
Mercier v. Inter-Tel (Delaware), Inc.
929 A.2d 786 (Court of Chancery of Delaware, 2007)
Schnell v. Chris-Craft Industries, Inc.
285 A.2d 437 (Supreme Court of Delaware, 1971)

Cite This Page — Counsel Stack

Bluebook (online)
Kellner v. AIM Immunotech Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/kellner-v-aim-immunotech-inc-delch-2023.